Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Operations (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash from Operations for 16 consecutive years, with 4637000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 193.11% to 4637000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 11188000.0, a 107.07% increase, with the full-year FY2025 number at 11188000.0, up 107.07% from a year prior.
  • Cash from Operations was 4637000.0 for Q4 2025 at Anika Therapeutics, down from 6870000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 6870000.0 in Q3 2025 to a low of 8293000.0 in Q2 2023.
  • A 5-year average of 1380450.0 and a median of 1822000.0 in 2021 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 656.34% in 2023; the steepest drop was 368.56% in 2023.
  • Anika Therapeutics' Cash from Operations stood at 4472000.0 in 2021, then plummeted by 89.24% to 481000.0 in 2022, then skyrocketed by 656.34% to 3638000.0 in 2023, then crashed by 56.51% to 1582000.0 in 2024, then skyrocketed by 193.11% to 4637000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Cash from Operations are 4637000.0 (Q4 2025), 6870000.0 (Q3 2025), and 189000.0 (Q2 2025).